Wells Fargo & Company Boosts Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $207.00
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target lifted by Wells Fargo & Company from $161.00 to $207.00 in a research note released on Tuesday, Benzinga reports. They currently have an equal weight rating on the biopharmaceutical company’s stock. Several other research firms have also issued reports on ALNY. Chardan Capital reissued a […]
More Stories
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Sees Large Decrease in Short Interest
SAB Biotherapeutics, Inc. (NASDAQ:SABS – Get Free Report) was the target of a significant decrease in short interest in the...
Valmet Oyj (OTCMKTS:VOYJF) Sees Large Decrease in Short Interest
Valmet Oyj (OTCMKTS:VOYJF – Get Free Report) was the recipient of a significant drop in short interest during the month...
Ubisoft Entertainment SA (OTCMKTS:UBSFY) Sees Significant Decrease in Short Interest
Ubisoft Entertainment SA (OTCMKTS:UBSFY – Get Free Report) was the target of a large drop in short interest in the...
SecureWorks Corp. (NASDAQ:SCWX) Short Interest Down 33.4% in October
SecureWorks Corp. (NASDAQ:SCWX – Get Free Report) was the target of a significant drop in short interest in October. As...
SecureWorks Corp. (NASDAQ:SCWX) Short Interest Down 33.4% in October
SecureWorks Corp. (NASDAQ:SCWX – Get Free Report) was the target of a significant drop in short interest in October. As...
SLM Co. (NASDAQ:SLMBP) Short Interest Update
SLM Co. (NASDAQ:SLMBP – Get Free Report) was the recipient of a large drop in short interest in October. As...